4147 Stock Overview
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TaiMed Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$87.70 |
| 52 Week High | NT$122.00 |
| 52 Week Low | NT$76.30 |
| Beta | 0.46 |
| 1 Month Change | 1.04% |
| 3 Month Change | -4.26% |
| 1 Year Change | -18.04% |
| 3 Year Change | 22.83% |
| 5 Year Change | -35.99% |
| Change since IPO | 321.63% |
Recent News & Updates
Recent updates
TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook
Apr 20
TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%
Mar 16TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.
Feb 09Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven
Jan 05
TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?
Dec 01Shareholder Returns
| 4147 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.4% | 7.4% | 2.5% |
| 1Y | -18.0% | -8.4% | 29.9% |
Return vs Industry: 4147 underperformed the TW Biotechs industry which returned -8.4% over the past year.
Return vs Market: 4147 underperformed the TW Market which returned 29.9% over the past year.
Price Volatility
| 4147 volatility | |
|---|---|
| 4147 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 4147's share price has been volatile over the past 3 months.
Volatility Over Time: 4147's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Jimmy Chang | www.taimedbiologics.com |
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody.
TaiMed Biologics Inc. Fundamentals Summary
| 4147 fundamental statistics | |
|---|---|
| Market cap | NT$23.94b |
| Earnings (TTM) | -NT$130.04m |
| Revenue (TTM) | NT$598.96m |
40.0x
P/S Ratio-184.1x
P/E RatioIs 4147 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4147 income statement (TTM) | |
|---|---|
| Revenue | NT$598.96m |
| Cost of Revenue | NT$350.44m |
| Gross Profit | NT$248.52m |
| Other Expenses | NT$378.57m |
| Earnings | -NT$130.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 41.49% |
| Net Profit Margin | -21.71% |
| Debt/Equity Ratio | 17.0% |
How did 4147 perform over the long term?
See historical performance and comparison